|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.02 USD | -0.78% |
|
+24.59% | +156.03% |
| Apr. 11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
| Apr. 03 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
Homology Medicines, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 112.96 million compared to USD 5.01 million a year ago. Basic loss per share from continuing operations was USD 35.1 compared to USD 1.62 a year ago.
Diluted loss per share from continuing operations was USD 35.1 compared to USD 1.62 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +156.03% | 334M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
Q32 BIO INC. 
